Quick Answer
CASTLE BIOSCIENCES INC reported Operating Income Loss of -$42.81 million for the year ending 2025.
- CASTLE BIOSCIENCES INC showed a decrease of -593.8% in Operating Income Loss from 2024 to 2025.
- This data is from CASTLE BIOSCIENCES INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$2.67 million | Q3 2018: -$2.85 million | Q1 2019: -$322.0 thousand | Q2 2019: $608.0 thousand | Q3 2019: $4.43 million | Q1 2020: $1.04 million | Q2 2020: -$645.0 thousand | Q3 2020: -$3.90 million | Q1 2021: -$4.28 million | Q2 2021: -$8.81 million | Q3 2021: -$11.81 million | Q1 2022: -$24.52 million | Q2 2022: -$3.97 million | Q3 2022: -$21.54 million | Q1 2023: -$31.52 million | Q2 2023: -$21.16 million | Q3 2023: -$9.64 million | Q1 2024: -$5.47 million | Q2 2024: $5.01 million | Q3 2024: $5.08 million | Q1 2025: -$27.93 million | Q2 2025: -$4.25 million | Q3 2025: -$6.80 million.
- Over the full 8 years of available data (2018 to 2025), CASTLE BIOSCIENCES INC's Operating Income Loss has declined by 1,016.0%.
- Historical annual values: Fiscal year 2025: -$42.81 million | Fiscal year 2024: $8.67 million | Fiscal year 2023: -$67.98 million | Fiscal year 2022: -$72.86 million | Fiscal year 2021: -$40.08 million | Fiscal year 2020: -$6.54 million | Fiscal year 2019: $7.33 million | Fiscal year 2018: -$3.84 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: